title: Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.
abstract: The majority of hypertensive patients, especially those with target organ damage, are likely to require multiple-drug therapy in order to reach blood pressure (BP) targets and reduce their risk of adverse vascular outcomes. The rationale for combination therapy with agents that block the renin-angiotensin system (RAS) and a calcium channel blocker (CCB) or diuretic is well founded in growing evidence. Recent published trials have shown that the combination of an RAS suppressor and a dihydropiridinic CCB would offer additional benefits independently of BP reduction. A telmisartan-amlodipine combination has demonstrated significantly greater BP reductions compared with each monotherapy component in the overall population, and in particular in patients with moderate to severe hypertension and high-risk patients. This combination is well tolerated with a safety profile similar to placebo and is consistent with the known safety profile of its monotherapy components.
authors.affiliation: Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.
authors.forename: Julian
authors.initials: J
authors.lastname: Segura
authors.forename: Luis M
authors.initials: LM
authors.lastname: Ruilope